Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 3/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295367 | 0.85 | ESR1 (0.88) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL5863215 | 0.82 | ESR1 (0.72) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL27593108 | 0.80 | ESR1 (1.00) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL5863831 | 0.79 | ESR1 (0.63) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL5863377 | 0.79 | NR3C1 (0.71) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL5864295 | 0.78 | ESR1 (0.58) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL5863852 | 0.77 | ESR1 (0.57) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL5863768 | 0.77 | ESR1 (0.60) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL6301442 | 0.76 | ESR1 (0.81) | ESR1NR3C1NR1I2CNR1CNR2 | |
| SCHEMBL5863975 | 0.75 | ESR1 (0.55) | ESR1NR3C1NR1I2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | ESR1 4/4885NR3C1 160/4885NR1I2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.